Announced
Financials
Tags
United States
biopharmaceutical company
Pharmaceuticals
Acquisition
Public
Pending
Single Bidder
Domestic
Majority
Friendly
Synopsis
Pyxis Oncology, a clinical-stage company focused on developing next-generation therapeutics, agreed to acquire Apexigen, a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, for $16m. “This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate innovation by adding humanized antibody generation to our Flexible Antibody Conjugation Technology ADC toolkit acquired from Pfizer, and expands our clinical pipeline into Phase 2 in select solid tumor types by leveraging our founding heritage of immuno-oncology expertise—all while maintaining our cash runway into 2025," Lara S. Sullivan, Pyxis Oncology M.D., President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.